Quick Answer
Amneal Pharmaceuticals, Inc. reported Total Revenue of $3.02 billion for fiscal year 2025.
Amneal Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $3.02B +8.0% |
$2.79B +16.7% |
$2.39B +8.2% |
$2.21B +5.7% |
$2.09B +5.1% |
$1.99B +22.5% |
| Revenue (ASC 606) | $3.02B +8.0% |
$2.79B +16.7% |
$2.39B +8.2% |
$2.21B +5.7% |
$2.09B +5.1% |
$1.99B +22.5% |
| Net Income | $72.06M +161.6% |
-$116.89M -39.2% |
-$83.99M +69.0% |
-$270.58M -2155.6% |
$13.16M -80.6% |
$67.79M +111.2% |
| Diluted EPS | $0.22 +157.9% |
-$0.38 +20.8% |
-$0.48 +44.2% |
-$0.86 -1328.6% |
$0.07 -88.5% |
$0.61 +122.3% |
| Total Assets | $3.68B +5.1% |
$3.50B +0.8% |
$3.47B -8.6% |
$3.80B -3.6% |
$3.94B -1.7% |
$4.01B +9.3% |
| Cash and Equivalents | $282.03M +155.1% |
$110.55M +20.8% |
$91.54M +252.4% |
$25.98M -89.5% |
$247.79M -27.4% |
$341.38M +125.8% |
| Long-Term Debt | $2.57B +18.7% |
$2.16B -9.4% |
$2.39B -7.9% |
$2.59B -3.3% |
$2.68B -2.0% |
$2.74B +4.8% |
| Stockholders Equity | -$70.79M +35.2% |
-$109.27M -652.4% |
$19.78M -93.4% |
$298.42M -17.2% |
$360.34M +18.8% |
$303.27M +30.7% |
| R&D Expense | $186.18M -2.4% |
$190.71M +16.3% |
$163.95M -16.2% |
$195.69M -3.1% |
$201.85M +12.2% |
$179.93M -4.3% |
| Operating Income | $394.10M +58.1% |
$249.33M +22.0% |
$204.37M +315.3% |
-$94.93M -162.2% |
$152.72M +67.5% |
$91.16M +136.7% |
| Gross Profit | $1.11B +9.1% |
$1.02B +24.4% |
$820.57M +4.6% |
$784.71M +2.0% |
$768.97M +22.4% |
$628.39M +78.0% |
| Shares Outstanding | — | — | — | — | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $784.51M | +11.7% | +8.3% |
| Revenue (ASC 606) | September 30, 2025 | $784.51M | +11.7% | +8.3% |
| Net Income | September 30, 2025 | $2.37M | +1618.6% | -89.4% |
| Diluted EPS | September 30, 2025 | $0.01 | — | -85.7% |
| Total Assets | September 30, 2025 | $3.60B | +4.0% | +5.2% |
| Cash and Equivalents | September 30, 2025 | $201.25M | +171.9% | +181.3% |
| Long-Term Debt | September 30, 2025 | $2.57B | +18.3% | +19.6% |
| Stockholders Equity | September 30, 2025 | -$109.46M | -17.2% | +2.4% |
| R&D Expense | September 30, 2025 | $63.35M | +3.7% | +32.1% |
| Operating Income | September 30, 2025 | $70.34M | -20.8% | -36.8% |
| Gross Profit | September 30, 2025 | $273.97M | +1.6% | -4.3% |
| Shares Outstanding | March 31, 2018 | 1,000 | — | +0.0% |
- Amneal Pharmaceuticals, Inc. reported Total Revenue of $3.02 billion for fiscal year 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +8.0% in Total Revenue compared to the prior fiscal year.
- Amneal Pharmaceuticals, Inc. reported Revenue (ASC 606) of $3.02 billion for fiscal year 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +8.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Amneal Pharmaceuticals, Inc. reported Net Income of $72.06 million for fiscal year 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +161.6% in Net Income compared to the prior fiscal year.
- Amneal Pharmaceuticals, Inc. reported Diluted EPS of $0.22 per share for fiscal year 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +157.9% in Diluted EPS compared to the prior fiscal year.
- Amneal Pharmaceuticals, Inc. reported Total Assets of $3.68 billion for fiscal year 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +5.1% in Total Assets compared to the prior fiscal year.
- Amneal Pharmaceuticals, Inc. reported Cash and Equivalents of $282.03 million for fiscal year 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +155.1% in Cash and Equivalents compared to the prior fiscal year.
- Amneal Pharmaceuticals, Inc. reported Long-Term Debt of $2.57 billion for fiscal year 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +18.7% in Long-Term Debt compared to the prior fiscal year.
- Amneal Pharmaceuticals, Inc. reported Stockholders Equity of -$70.79 million for fiscal year 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +35.2% in Stockholders Equity compared to the prior fiscal year.
- Amneal Pharmaceuticals, Inc. reported R&D Expense of $186.18 million for fiscal year 2025.
- Amneal Pharmaceuticals, Inc. showed a decrease of -2.4% in R&D Expense compared to the prior fiscal year.
- Amneal Pharmaceuticals, Inc. reported Operating Income of $394.10 million for fiscal year 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +58.1% in Operating Income compared to the prior fiscal year.
- Amneal Pharmaceuticals, Inc. reported Gross Profit of $1.11 billion for fiscal year 2025.
- Amneal Pharmaceuticals, Inc. showed an increase of +9.1% in Gross Profit compared to the prior fiscal year.
- Amneal Pharmaceuticals, Inc. reported Shares Outstanding of 1.0 thousand shares for fiscal year 2017.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: